How beta blocker medicines might protect bone after menopause
Official title: Molecular and cellular mechanisms of prevention of bone loss by beta blockers
Funded at Mainehealth · NIH-11189800 · Data updated 2026-11-12
This research looks at whether certain beta blocker medicines can help protect bone density in women after menopause.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mainehealth NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 21, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $383,236 |
| NIH project number | 5R01AR081040-04 |
| Project ID | NIH-11189800 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are postmenopausal women at risk for osteoporosis or early bone loss who might be eligible for beta blocker treatment or sample donation for genetic/molecular studies.
✕Less likely to help
People with bone loss from causes unrelated to menopause, those with contraindications to beta blockers, or men are less likely to benefit from this research.
What this research studies
Researchers will study why beta blockers appear to help prevent postmenopausal bone loss by combining human genetic and molecular data with lab experiments. They will examine gene differences (like ADRB1) and small RNA molecules (such as miR-19a-3p) that may change how people respond to beta blockers. In the lab they will use mouse and cell studies to see how these drugs affect bone cells called osteoclasts and osteoblasts. The goal is to link lab findings to human data so doctors can better choose which beta blocker and which patients might benefit most.
Why it matters
Potential benefit: If successful, this work could guide safer, more personalized use of beta blockers to help prevent bone loss after menopause.
How similar studies have gone: Human observational studies have linked B1-selective beta blockers with better bone outcomes while prior mouse work pointed to B2 receptors, so parts of this approach are supported but the exact mechanism and personalized links are still novel.
Where this research is happening
-
Mainehealth
Portland, United States Active
Researchers
- Principal investigator: Motyl, Katherine Jean — Mainehealth
- Study coordinator: Motyl, Katherine Jean
Related research
Other NIH-funded projects on the same topics.
-
How HIV and HIV meds affect jaw bone and teeth
This project looks at how HIV, its treatment, and immune changes may cause jawbone and tooth loss in people living with HIV.
-
Periodontitis and HIV treatment–related bone loss in the jaw and teeth
This project studies how HIV and its treatment affect jawbone and tooth loss in people living with HIV, aiming to understand and reduce bone damage around teeth.
-
Molecular clues to bone loss from disuse
This project looks for genes that influence bone loss when people or animals don’t move much, like during bed rest or spaceflight.
-
Oral-Gut–Bone Links in Periodontitis and Bone Loss
This research explores how gum disease could affect bone health by studying the connection between the mouth, gut, and bones in adults.
-
Bone health restoration after spinal cord injury through Wnt signaling and exercise
Aims to find a long-term way to preserve and rebuild bone in people with spinal cord injury, especially veterans, by combining exercise and bone-building signals.
-
Urine cadmium and bone health in older adults
This project looks at whether long-term cadmium exposure, measured in urine, is linked to bone loss and fractures in older adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.